Latest news with #Matteis
Business Insider
12-07-2025
- Business
- Business Insider
Analysts Are Bullish on Top Healthcare Stocks: Neurogene (NGNE), Cogent Biosciences (COGT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurogene (NGNE – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Neurogene (NGNE) Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene on July 7 and set a price target of $46.00. The company's shares closed last Friday at $21.43, close to its 52-week low of $13.47. According to Matteis is a 3-star analyst with an average return of 2.8% and a 43.2% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Sionna Therapeutics, Inc., KalVista Pharmaceuticals, and BioMarin Pharmaceutical. Currently, the analyst consensus on Neurogene is a Strong Buy with an average price target of $38.20, implying a 76.5% upside from current levels. In a report issued on June 30, BMO Capital also maintained a Buy rating on the stock with a $26.00 price target. Cogent Biosciences (COGT) In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences, with a price target of $20.00. The company's shares closed last Friday at $10.98. According to Slutsky has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.6% and a 38.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Abivax SA Sponsored ADR, and Olema Pharmaceuticals. Cogent Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $18.64, a 74.7% upside from current levels. In a report issued on June 30, Citi also maintained a Buy rating on the stock with a $15.00 price target.
Business Insider
22-06-2025
- Business
- Business Insider
Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $42.00. The company's shares closed last Friday at $29.09. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Matteis is a 3-star analyst with an average return of 1.2% and a 41.20% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Neurocrine, and uniQure. In addition to Stifel Nicolaus, Alkermes also received a Buy from UBS's Ashwani Verma in a report issued on June 17. However, on June 10, RBC Capital maintained a Hold rating on Alkermes (NASDAQ: ALKS).
Business Insider
25-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Viridian Therapeutics (VRDN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vigil Neuroscience Inc (VIGL – Research Report), Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) and Viridian Therapeutics (VRDN – Research Report). Confident Investing Starts Here: Vigil Neuroscience Inc (VIGL) In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Vigil Neuroscience Inc, with a price target of $11.00. The company's shares closed last Friday at $7.89. According to Matteis is a 3-star analyst with an average return of 1.2% and a 40.9% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., Sionna Therapeutics, Inc., and KalVista Pharmaceuticals. Vigil Neuroscience Inc has an analyst consensus of Hold, with a price target consensus of $9.50. Fisher & Paykel Healthcare Corporation Limited received a Hold rating and a A$35.80 price target from Jefferies analyst Vanessa Thomson on May 23. The company's shares closed last Thursday at $20.70. Thomson has an average return of 22.2% when recommending Fisher & Paykel Healthcare Corporation Limited. According to Thomson is ranked #1098 out of 9562 analysts. Currently, the analyst consensus on Fisher & Paykel Healthcare Corporation Limited is a Moderate Buy with an average price target of $25.30. Viridian Therapeutics (VRDN) Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics today and set a price target of $41.00. The company's shares closed last Friday at $13.57, close to its 52-week low of $11.40. According to CFA 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.8% and a 40.7% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Third Harmonic Bio, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viridian Therapeutics with a $38.80 average price target, representing a 189.8% upside. In a report issued on May 20, Wedbush also maintained a Buy rating on the stock with a $41.00 price target.
Yahoo
16-04-2025
- Business
- Yahoo
Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the . In this article, we are going to take a look at where Mereo BioPharma Group (NASDAQ:MREO) stands against other biotech penny stocks. Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas. First the vaccine approvals and the subsequent resurgence of new vaccines over the past two decades, and then the establishment of the cell and gene therapy field that he's credited for. He was involved in developing policies aimed at optimizing the process of bringing several innovative products to the market. Following his resignation, a substantial number of other departures are also anticipated, which implies upcoming destabilization at the FDA for its existing expertise and processes. Stifel head of biotech research Paul Matteis suggests looking for biotech names not dependent on the FDA while this sector uncertainty lasts. On March 31, Paul Matteis appeared on CNBC's 'The Exchange' and noted that biotech investors, particularly those who are focused on developmental-stage companies, are now facing risk. These include scientific, clinical trials, commercial, patent, competition, and regulatory risks. Hence, investors now need to be more selective about their stock selections. Previously, the FDA has been a stabilizing force for the biotech sector and is known for accelerating approvals in areas such as rare diseases and biomarkers. But recent developments have introduced unpredictability. Matteis highlighted that there could be short-term delays in drug approvals due to personnel changes at the FDA, such as the recent departure of the head of the Center for Drug Evaluation and Research (CEDAR). Investors may even need to reevaluate agreements between companies and the FDA regarding drug approvals. While this doesn't make biotech investments completely unsustainable, it does shift the focus toward companies with more predictable growth prospects. This could point to specifically commercial-stage firms or those less reliant on FDA consistency. Talking about vaccine stocks particularly, Matteis pointed out that as much as Peter Marks influenced vaccine-related decisions, he also impacted broader areas like gene therapies and oncology. He fostered innovation through programs like breakthrough therapy designations and initiatives that were aimed at streamlining approvals. Investors are now gravitating toward companies with de-risked profiles that are less dependent on FDA flexibility. Matteis noted that the companies relatively outperforming right now are those that have their success tied to commercial launches rather than regulatory decisions. We sifted through ETFs, stock screeners, and financial media reports to compile a list of the top biotech penny stocks that were trading below $5 as of April 14. We then selected the 13 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey's database which tracks the moves of over 1000 elite money managers. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A laboratory team in white coats working and testing new biopharmaceuticals. Share Price as of April 14: $1.95 Number of Hedge Fund Holders: 30 Mereo BioPharma Group (NASDAQ:MREO) develops and commercializes therapeutics for the treatment of oncology and rare diseases. It develops Etigilimab (MPH-313), which is an antibody T-cell immunoreceptor with Ig and ITIM domains. The company is also developing Navicixizumab (OMP-305B83), Acumapimod (BCT-197), a p38 MAP kinase inhibitor, and Leflutrozole (BGS-649). Mereo is also focused on setrusumab (UX143), which is an investigational and fully human monoclonal antibody that is being developed for osteogenesis imperfecta (OI). Its action mechanism involves inhibiting sclerostin, which is a protein that negatively regulates bone formation. The intended effect of setrusumab is to increase bone density and reduce fractures in patients with OI. Mereo's partner Ultragenyx is conducting two Phase 3 studies: one is Orbit in patients aged 5-25, with a second interim analysis in mid-2025 and a potential final analysis in Q4 2025. The other is Cosmic in patients aged 2 to under 7. Positive results could lead to US and EU regulatory filings. The partnership includes ~$245 million in potential milestone payments and royalties to Mereo on Ultragenyx's sales. Mereo BioPharma Group (NASDAQ:MREO) is preparing for a potential European launch of setrusumab. Overall, MREO ranks 7th on our list of the best biotech penny stocks to buy according to hedge funds. While we acknowledge the growth potential of MREO, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than MREO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
16-04-2025
- Business
- Yahoo
Is Sana Biotechnology Inc. (NASDAQ:SANA) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the . In this article, we are going to take a look at where Sana Biotechnology Inc. (NASDAQ:SANA) stands against other biotech penny stocks. Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas. First the vaccine approvals and the subsequent resurgence of new vaccines over the past two decades, and then the establishment of the cell and gene therapy field that he's credited for. He was involved in developing policies aimed at optimizing the process of bringing several innovative products to the market. Following his resignation, a substantial number of other departures are also anticipated, which implies upcoming destabilization at the FDA for its existing expertise and processes. Stifel head of biotech research Paul Matteis suggests looking for biotech names not dependent on the FDA while this sector uncertainty lasts. On March 31, Paul Matteis appeared on CNBC's 'The Exchange' and noted that biotech investors, particularly those who are focused on developmental-stage companies, are now facing risk. These include scientific, clinical trials, commercial, patent, competition, and regulatory risks. Hence, investors now need to be more selective about their stock selections. Previously, the FDA has been a stabilizing force for the biotech sector and is known for accelerating approvals in areas such as rare diseases and biomarkers. But recent developments have introduced unpredictability. Matteis highlighted that there could be short-term delays in drug approvals due to personnel changes at the FDA, such as the recent departure of the head of the Center for Drug Evaluation and Research (CEDAR). Investors may even need to reevaluate agreements between companies and the FDA regarding drug approvals. While this doesn't make biotech investments completely unsustainable, it does shift the focus toward companies with more predictable growth prospects. This could point to specifically commercial-stage firms or those less reliant on FDA consistency. Talking about vaccine stocks particularly, Matteis pointed out that as much as Peter Marks influenced vaccine-related decisions, he also impacted broader areas like gene therapies and oncology. He fostered innovation through programs like breakthrough therapy designations and initiatives that were aimed at streamlining approvals. Investors are now gravitating toward companies with de-risked profiles that are less dependent on FDA flexibility. Matteis noted that the companies relatively outperforming right now are those that have their success tied to commercial launches rather than regulatory decisions. We sifted through ETFs, stock screeners, and financial media reports to compile a list of the top biotech penny stocks that were trading below $5 as of April 14. We then selected the 13 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey's database which tracks the moves of over 1000 elite money managers. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. Share Price as of April 14: $1.76 Number of Hedge Fund Holders: 24 Sana Biotechnology Inc. (NASDAQ:SANA) utilizes engineered cells as medicines and develops ex vivo and in vivo cell engineering platforms for different therapeutic areas, such as type 1 diabetes, B cell-mediated autoimmune diseases, and oncology. It has an option and license agreement with Beam Therapeutics Inc. for the use of Beam's proprietary CRISPR Cas12b nuclease editing technology. In Q4 2024, Sana reported positive preliminary 12-week clinical results from its UP421 study. This study involves hypoimmune-modified pancreatic islet cells and demonstrated stable C-peptide production. C-peptide is a biomarker for insulin production. It indicates that the transplanted cells are functioning as intended and don't require immunosuppression. Sana is investing in its Type 1 Diabetes program, with a focus on developing SC451. Preclinical data for SC451 has shown 15-month durability of glycemic control in a mouse model, and no observed histologic abnormalities. The goal is for SC451 to be a single-treatment therapy for restoring normal blood glucose levels in patients with type 1 diabetes. Sana Biotechnology Inc.'s (NASDAQ:SANA) anticipates sharing additional data from this program in 2025 and aims to file an IND application as early as 2026. Overall, SANA ranks 13th on our list of the best biotech penny stocks to buy according to hedge funds. While we acknowledge the growth potential of SANA, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than SANA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
